Live Micron Technology Inc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Oncternal Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Oncternal Therapeutics, Inc.

ONCT

Oncternal Therapeutics, Inc.

About Oncternal Therapeutics, Inc.

Oncternal Therapeutics is a clinical-stage biopharmaceutical company developing innovative oncology therapies targeting unmet needs in prostate cancer and hematological malignancies. Its pipeline includes novel agents like ONCT-534, a dual-action androgen receptor inhibitor, and ROR1-targeted cell therapies and antibodies. The company focuses on precision medicine, leveraging unique mechanisms of action, and collaborates with academic and industry partners to advance cancer treatments.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Oncternal Therapeutics, Inc.

1
1
Oncternal Therapeutics, Inc. Oncternal Therapeutics Reports Improved Financials, Strategic Shift Amid Ongoing Challenges

Via official filing (AI summary) | over 1 year ago | 0 comments